CAA Specific Neutra™ Antibody Products

Struggling with prolonged therapeutic development timelines or inconsistent targeting of tumor-associated antigens? Creative Biolabs' CAA specific Neutra™ antibodies utilize advanced epitope mapping and affinity maturation technologies to deliver high-precision tools for accelerating cancer research and therapeutic discovery.

Introduction to CAA

Carcinoma-associated antigen (CAA), also called tumor-associated antigens (TAAs), is a membrane-bound glycoprotein overexpressed in multiple malignancies, including colorectal, pancreatic, and breast cancers. Its dysregulated expression correlates with tumor progression, metastasis, and immune evasion, making it a critical biomarker and therapeutic target.

Fig.1 Feature of TAAs expression.¹

• Basic Insights

CAA is a conserved oncoprotein expressed primarily on the surface of carcinoma cells. It facilitates cell-cell adhesion and modulates interactions within the tumor microenvironment, promoting tumor survival and resistance to apoptosis.

• Structural Features

CAA comprises three extracellular immunoglobulin-like domains, a transmembrane helix, and a short cytoplasmic tail. Its N-terminal domain mediates ligand binding, while the C-terminal region interacts with intracellular signaling adaptors. Structural studies reveal that glycosylation at specific residues enhances its stability and ligand-binding capacity.

• Signaling Pathways

CAA activates pro-survival pathways, including PI3K/AKT and NF-κB, through interactions with integrins and growth factor receptors. Additionally, it suppresses antitumor immune responses by downregulating MHC class I expression on cancer cells, thereby impairing T-cell recognition.

• Associated Pathologies

Elevated CAA levels are linked to advanced-stage cancers, poor prognosis, and resistance to chemotherapy. It is also implicated in cancer cachexia, where systemic inflammation driven by CAA-expressing tumors accelerates muscle wasting.

Therapeutic and Diagnostic Applications of Anti-CAA Antibodies

• Inhibiting Tumor Progression

Neutralizing antibodies against CAA suppress metastasis by interfering with cancer cell adhesion and migration. Preclinical studies show reduced tumor burden in models of peritoneal carcinomatosis, suggesting their potential to prevent widespread dissemination, a major cause of cancer mortality.

• Enhancing Immunotherapy

By blocking CAA-mediated MHC class I suppression, these antibodies restore T-cell-mediated tumor killing. This synergy with checkpoint inhibitors is being explored in clinical trials for refractory cancers, providing a compelling strategy to overcome primary or acquired resistance to existing immunotherapies.

• Biomarker-Driven Diagnostics

Anti-CAA antibodies enable quantitative detection of circulating tumor cells and serum CAA levels, aiding early diagnosis and monitoring treatment response. A 2024 study validated their utility in predicting recurrence risk in stage II colorectal cancer, offering a precise, non-invasive tool for patient stratification.

• Targeted Drug Delivery

Conjugating anti-CAA antibodies to chemotherapeutic agents enhances tumor-specific drug accumulation while sparing healthy tissues, a strategy under investigation for triple-negative breast cancer, promising reduced systemic toxicity and improved therapeutic windows.

Our Anti-CAA Neutralizing Antibodies

Creative Biolabs' anti-CAA neutralizing antibodies are engineered to block ligand binding and disrupt downstream signaling. Key advantages include:

- High Specificity: Affinity-optimized clones minimize off-target effects.

- Functional Validation: Demonstrated efficacy in inhibiting tumor growth in xenograft models.

- Versatility: Compatible with flow cytometry, immunohistochemistry, and in vivo neutralization assays.

Creative Biolabs' CAA specific Neutra™ antibodies are rigorously validated to empower breakthrough discoveries in cancer biology and therapy development. Contact our team today to discuss custom solutions for your research project.

REFERENCE

1. Jia, Wenqing, et al. "Colorectal cancer vaccines: The current scenario and future prospects." Frontiers in Immunology 13 (2022): 942235. Distributed under Open Access license CC BY 4.0. The image was modified by extracting and using only part of the original image. https://doi.org/10.3389/fimmu.2022.942235